Anavex Life Sciences Corp (AVXL)

[Investor2014]

So far no Anavex RCT has gone extremely well, as in being a pivotal P3 meeting all endpoints for traditional approval.

So far, every trial has gone extremely well. That could change

Without exception none of them have fully met all endpoints per protocol and instead left out outcome measures, used Odds Ratios or AUC inappropriately to impress retail and apparently even the occasional ex-biotech executive.

All the trials have however shown encouraging signals and good safety profile in indications with high unmet need and will no doubt be very useful for designing future trials in same and/or other indications. There is clearly a chance that AD and hopefully the STILL upcoming Rett results may achieve approval likely limited to subgroups of patients, while most requiring further confirmatory trials for continued marketing authorisation and label expansion.